SG11201402661TA - Therapeutic agents comprising insulin amino acid sequences - Google Patents
Therapeutic agents comprising insulin amino acid sequencesInfo
- Publication number
- SG11201402661TA SG11201402661TA SG11201402661TA SG11201402661TA SG11201402661TA SG 11201402661T A SG11201402661T A SG 11201402661TA SG 11201402661T A SG11201402661T A SG 11201402661TA SG 11201402661T A SG11201402661T A SG 11201402661TA SG 11201402661T A SG11201402661T A SG 11201402661TA
- Authority
- SG
- Singapore
- Prior art keywords
- amino acid
- acid sequences
- therapeutic agents
- insulin amino
- insulin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161563985P | 2011-11-28 | 2011-11-28 | |
| PCT/US2012/066795 WO2013082116A1 (fr) | 2011-11-28 | 2012-11-28 | Agents thérapeutiques comprenant des séquences d'acides aminés d'insuline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201402661TA true SG11201402661TA (en) | 2014-08-28 |
Family
ID=48536000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201402661TA SG11201402661TA (en) | 2011-11-28 | 2012-11-28 | Therapeutic agents comprising insulin amino acid sequences |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20130150291A1 (fr) |
| EP (1) | EP2785367A4 (fr) |
| JP (1) | JP2014534265A (fr) |
| KR (1) | KR20140103985A (fr) |
| CN (1) | CN104080473A (fr) |
| AU (1) | AU2012346058A1 (fr) |
| BR (1) | BR112014012789A2 (fr) |
| CA (1) | CA2856967A1 (fr) |
| HK (1) | HK1202067A1 (fr) |
| IL (1) | IL232781A0 (fr) |
| MX (1) | MX2014006391A (fr) |
| RU (1) | RU2014126244A (fr) |
| SG (1) | SG11201402661TA (fr) |
| WO (1) | WO2013082116A1 (fr) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
| US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
| EP2926825A1 (fr) | 2008-06-27 | 2015-10-07 | Duke University | Agents thérapeutiques comprenant des peptides de type élastine |
| US9561262B2 (en) | 2011-06-06 | 2017-02-07 | Phasebio Pharmaceuticals, Inc. | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
| WO2014081849A1 (fr) | 2012-11-20 | 2014-05-30 | Phasebio Pharmaceuticals, Inc. | Formulations de principes actifs pour une libération prolongée |
| US20150361154A1 (en) * | 2013-01-15 | 2015-12-17 | Phasebio Pharmaceuticals, Inc. | Therapeutic agents, compositions, and methods for glycemic control |
| EP3139949B1 (fr) | 2014-05-08 | 2020-07-29 | Phasebio Pharmaceuticals, Inc. | Compositions comprenant un protéine de fusion de vip-elp pour l'utilisation dans le traitement de la fibrose kystique |
| EP3220936A4 (fr) * | 2014-11-21 | 2018-08-22 | Phasebio Pharmaceuticals, Inc. | Protéines de fusion elp pour libération contrôlée et prolongée |
| JP6824888B2 (ja) | 2015-02-09 | 2021-02-03 | フェーズバイオ ファーマシューティカルズ，インコーポレイテッド | 筋肉の疾患および障害を治療するための方法および組成物 |
| TW201718627A (zh) | 2015-06-11 | 2017-06-01 | 梅茲製藥有限兩合公司 | 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞 |
| EP3124495A1 (fr) * | 2015-07-31 | 2017-02-01 | Centre National de la Recherche Scientifique (C.N.R.S.) | Dérivés de polypeptides de type élastine et leurs utilisations |
| US11458205B2 (en) | 2015-08-04 | 2022-10-04 | Duke University | Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same |
| CN105061566A (zh) * | 2015-09-05 | 2015-11-18 | 苏州普罗达生物科技有限公司 | 拟胰岛素多肽及其应用 |
| CN108473548A (zh) * | 2015-09-24 | 2018-08-31 | 韩美药品股份有限公司 | 胰岛素生产方法 |
| KR101815080B1 (ko) * | 2015-11-03 | 2018-01-04 | 재단법인대구경북과학기술원 | 췌장소도세포 및 엘라스틴 유사 인공 세포외 기질을 포함하는 당뇨병 치료용 약학적 조성물 |
| US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
| AU2017227978B2 (en) | 2016-03-02 | 2022-03-10 | Merz Pharma Gmbh & Co. Kgaa | Composition comprising botulinum toxin |
| WO2017189860A1 (fr) | 2016-04-27 | 2017-11-02 | The Regents Of The University Of California | Préparation de résidus fonctionnels d'homocystéine dans des polypeptides et des peptides |
| AU2017261216B2 (en) * | 2016-05-06 | 2023-08-03 | Immunoforge Co., Ltd. | ELP fusion proteins for controlled and sustained release |
| US11467156B2 (en) | 2016-06-01 | 2022-10-11 | Duke University | Nonfouling biosensors |
| KR20190064600A (ko) | 2016-09-23 | 2019-06-10 | 듀크 유니버시티 | Lcst 거동을 갖는 비구조화된 비-반복적 폴리펩티드 |
| US11220467B2 (en) | 2017-01-11 | 2022-01-11 | Recycle Track Systems, Inc. | Indoor food waste fermentation and recycling process |
| WO2018132732A1 (fr) | 2017-01-12 | 2018-07-19 | Duke University | Biomatériaux hybrides lipide-polypeptide génétiquement codés qui offrent un auto-assemblage hiérarchique déclenché par la température |
| WO2018213320A1 (fr) | 2017-05-15 | 2018-11-22 | Duke University | Production recombinante de matériaux hybrides lipidiques-biopolymères qui s'auto-assemblent et encapsulent des agents |
| US11952601B2 (en) | 2017-06-20 | 2024-04-09 | Merz Pharma Gmbh & Co. Kgaa | Recombinant botulinum toxin with increased duration of effect |
| WO2019006374A1 (fr) | 2017-06-30 | 2019-01-03 | Duke University | Ordre et désordre en tant que principe de conception pour des réseaux de biopolymère sensibles à des stimuli |
| ES2930237T3 (es) | 2017-07-06 | 2022-12-09 | Merz Pharma Gmbh & Co Kgaa | Neurotoxinas botulínicas recombinantes nuevas con mayor duración de efectos |
| EP3829622A4 (fr) | 2018-08-02 | 2022-05-11 | Duke University | Protéines de fusion à double agoniste |
| KR102456958B1 (ko) * | 2019-05-14 | 2022-10-21 | 강원대학교 산학협력단 | 당뇨병성 합병증의 예방 또는 치료용 약제학적 조성물 |
| CN111939244A (zh) | 2019-05-14 | 2020-11-17 | 阿莫生命科学有限公司 | 用于预防或治疗糖尿病并发症的药物组合物 |
| US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
| JPWO2021112249A1 (fr) * | 2019-12-06 | 2021-06-10 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1030688B1 (fr) * | 1997-11-12 | 2004-09-29 | Alza Corporation | Procede d'administration dermale de polypeptides |
| US7846445B2 (en) * | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
| CA2634034A1 (fr) * | 2005-12-20 | 2007-06-28 | Duke University | Procedes et compositions pour l'administration d'agents actifs a proprietes pharmacologiques ameliorees |
| JP2009526856A (ja) * | 2006-02-15 | 2009-07-23 | イムクローン・リミテッド・ライアビリティ・カンパニー | 抗体製剤 |
| CN101616685B (zh) * | 2006-03-06 | 2013-07-24 | 阿穆尼克斯运营公司 | 非结构化重组聚合物和其应用 |
| EP2926825A1 (fr) * | 2008-06-27 | 2015-10-07 | Duke University | Agents thérapeutiques comprenant des peptides de type élastine |
| WO2010014689A1 (fr) * | 2008-07-29 | 2010-02-04 | Phasebio Pharmaceuticals, Inc. | Formulations pharmaceutiques comprenant des protéines analogues à de l'élastine |
| BR112012001988A2 (pt) * | 2009-07-31 | 2017-05-09 | Sanofi Aventis Deutschland | composição de insulina de ação prolongada |
| JP5801807B2 (ja) * | 2009-08-14 | 2015-10-28 | フェーズバイオ ファーマシューティカルズ，インコーポレイテッド | 修飾された血管作動性腸管ペプチド |
-
2012
- 2012-11-28 JP JP2014543618A patent/JP2014534265A/ja active Pending
- 2012-11-28 KR KR1020147017232A patent/KR20140103985A/ko not_active Application Discontinuation
- 2012-11-28 WO PCT/US2012/066795 patent/WO2013082116A1/fr active Application Filing
- 2012-11-28 EP EP12852785.0A patent/EP2785367A4/fr not_active Withdrawn
- 2012-11-28 US US13/687,776 patent/US20130150291A1/en not_active Abandoned
- 2012-11-28 MX MX2014006391A patent/MX2014006391A/es unknown
- 2012-11-28 RU RU2014126244A patent/RU2014126244A/ru not_active Application Discontinuation
- 2012-11-28 SG SG11201402661TA patent/SG11201402661TA/en unknown
- 2012-11-28 CN CN201280068260.1A patent/CN104080473A/zh active Pending
- 2012-11-28 CA CA2856967A patent/CA2856967A1/fr not_active Abandoned
- 2012-11-28 BR BR112014012789A patent/BR112014012789A2/pt not_active IP Right Cessation
- 2012-11-28 AU AU2012346058A patent/AU2012346058A1/en not_active Abandoned
-
2014
- 2014-05-25 IL IL232781A patent/IL232781A0/en unknown
- 2014-06-13 US US14/304,617 patent/US20140364362A1/en not_active Abandoned
-
2015
- 2015-03-16 HK HK15102642.1A patent/HK1202067A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014534265A (ja) | 2014-12-18 |
| HK1202067A1 (en) | 2015-09-18 |
| EP2785367A1 (fr) | 2014-10-08 |
| KR20140103985A (ko) | 2014-08-27 |
| BR112014012789A2 (pt) | 2019-09-24 |
| WO2013082116A1 (fr) | 2013-06-06 |
| IL232781A0 (en) | 2014-07-31 |
| CN104080473A (zh) | 2014-10-01 |
| EP2785367A4 (fr) | 2015-06-17 |
| RU2014126244A (ru) | 2016-01-27 |
| CA2856967A1 (fr) | 2013-06-06 |
| US20140364362A1 (en) | 2014-12-11 |
| AU2012346058A1 (en) | 2014-06-12 |
| MX2014006391A (es) | 2014-09-22 |
| US20130150291A1 (en) | 2013-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1202067A1 (en) | Therapeutic agents comprising insulin amino acid sequences | |
| HK1243427A1 (zh) | 治療肽 | |
| HK1200851A1 (en) | Etanercept formulations stabilized with amino acids | |
| EP2771033A4 (fr) | Formulations protéiques contenant des acides aminés | |
| IL232588A0 (en) | Subcutaneous therapeutic use of 4-dpp inhibitor | |
| AU343318S (en) | Medicine injector | |
| GB201114212D0 (en) | Therapeutic agents | |
| GB201119401D0 (en) | Therapeutic agents | |
| EP2709670A4 (fr) | Administration ciblée de protéines à travers la barrière hémato-encéphalique | |
| IL227558A0 (en) | A therapeutic agent for tumors | |
| EP2724740A4 (fr) | Seringue pré-remplie | |
| EP2783256A4 (fr) | Lunettes thérapeutiques | |
| EP2724735A4 (fr) | Fournitures médicales | |
| ZA201502595B (en) | Therapeutic methods | |
| ZA201402171B (en) | Amino acid sequences for controlling pathogens | |
| ZA201308176B (en) | Therapeutic treatment | |
| EP2739608A4 (fr) | Activateurs de la sécrétion d'insuline | |
| GB201102913D0 (en) | Novel therapeutic | |
| GB201115558D0 (en) | Therapeutic agents | |
| GB201110614D0 (en) | Therapeutic agents | |
| GB201101128D0 (en) | Therapeutic agents | |
| GB201110895D0 (en) | Therapeutic use |